Press releases
Biofidelity to present ASPYRE®-Lung data at AACR 2024
Apr 5. 2024
Biofidelity announced that new data from its breakthrough product ASPYRE-Lung will be presented in three scientific posters, including a Late Breaking Abstract (LBA) at AACR 2024.
Biofidelity raises $24 million in new financing to accelerate commercialization and expand product pipeline
Apr 3. 2024
Biofidelity successfully completed a financing round totalling $24 million bringing total funding raised since the Company was founded in 2019 to $60 million.
Fidelis Sustainability Distribution and Biofidelity Collaborate to Bring Rapid Precision Genomic Testing to Veterans Administration (VA) Customers
Jan 24. 2024
Biofidelity and Fidelis Sustainability Distribution (Fidelis) today announced that they have entered into an agreement to make ASPYRE®-Lung available to VA Medical Centers and active military institutions across the US.
Biofidelity launches ASPYRE®-Lung reagents, enabling laboratories worldwide to perform rapid precision genomic analysis
Dec 6. 2023
ASPYRE-Lung Research Use Only (RUO) reagents enable localized testing and rapid results across all NCCN guideline recommended genes for non-small cell lung cancer (NSCLC).
Biofidelity announces the commercial launch of ASPYRE®-Lung in the US
Sep 5. 2023
Biofidelity, a revolutionary genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world, today announced the commercial launch of ASPYRE®-Lung in the US.
Biofidelity Introduces ASPYRE®-Lung at ASCO 2023
May 25. 2023
ASPYRE simplifies and accelerates the detection of actionable biomarkers in both DNA and RNA from either tissue or plasma within two days.
Matt Franklin, MBA, appointed as Biofidelity Non-Executive Director
Nov 17. 2022
Biofidelity has expanded its Board of Directors to include Matt Franklin, MBA, who will join as a Non-Executive Director.
Biofidelity announces presentation of new data on novel genomic technology at AMP 2022
Oct 28. 2022
ASPYRE simplifies & accelerates the detection of biomarkers in both DNA & RNA to facilitate selection of the most effective targeted cancer treatments
New data demonstrates novel genomic technology provides ultra-sensitive detection of gene fusions from RNA
Oct 18. 2022
Current sequencing methods miss gene fusions for many non-small cell lung cancer patients denying them access to targeted therapies.
Biofidelity granted key patents in US, Europe, and China
Oct 11. 2022
New patents in global markets strengthen and secure intellectual property for innovative platform technology designed to remove the noise from genomic data
Biofidelity Raises $23M in Series A+ Financing led by Octopus Ventures to Launch ASPYRE Technology | Biofidelity
Feb 1. 2022
Funding will enable expansion of US presence and acceleration of the commercialization of ASPYRE Cambridge, UK, February 1, 2022 — Biofidelity, a pioneer in …
Biofidelity Adds Lee N. Newcomer, MD to Scientific Advisory Board Ahead of ASPYRE Launch | Biofidelity
Jan 6. 2022
Fast, multi-gene biomarker test designed to make targeted precision cancer treatments available to more patients Cambridge, UK, January 6, 2022 — …
New California Law Increases Access to Biomarker Testing for Late-Stage Cancer Patients | Biofidelity
Oct 13. 2021
SB 535 aims to reduce delays for the genetic testing that’s essential for selecting targeted, more effective cancer treatments Cambridge, UK, October 13, …
Successful alpha testing of Biofidelity’s ASPYRE-Lung reagents demonstrates breakthrough capabilities and ease of use | Biofidelity
Sep 14. 2021
ASPYRE-Lung panel set up and multiple samples analyzed in US & UK test labs in as little as one day Consistent performance demonstrated across test sites …
Biofidelity opens US headquarters and new cancer diagnostic laboratory | Biofidelity
Jul 28. 2021
Facility in RTP North Carolina will enable US launch of precision diagnostics using breakthrough ASPYRE technology Cambridge, UK, 28 July 2021 – Biofidelity …
Biofidelity Announces Formation of Scientific Advisory Board | Biofidelity
Jul 15. 2021
New Scientific Advisory Board combines decades of industry, academic and patient advocacy oncology leadership to help guide development & …
Biofidelity wins Start Up of the Year at the Cambridge Independent Science & Technology Awards | Biofidelity
Apr 16. 2021
Cambridge, UK 16 April 2021 – Biofidelity Ltd, the cancer diagnostics company, today announced it has won Start Up of the Year at the Cambridge Independent …
Biofidelity granted key patent in US for breakthrough cancer diagnostic technology | Biofidelity
Apr 7. 2021
Patent supports the unique potential of Biofidelity’s technology to deliver ultra-sensitive detection of guideline-recommended tumor markers Cambridge, UK, 7 …
Biofidelity announces first peer reviewed publication of breakthrough ASPYRE technology | Biofidelity
Mar 23. 2021
Publication validates the ability of ASPYRE to detect single copies of somatic variants in tissue and plasma Cambridge, UK, 23 March 2021 – Biofidelity …
Biofidelity appoints Wendy J. Levin MD MS as Chief Medical Officer | Biofidelity
Jan 28. 2021
Experienced US-based medical oncologist joins Biofidelity prior to launch of first diagnostic product US-trained oncologist & hematologist with over 15 …
Biofidelity appoints Robert Osborne as Chief Operating Officer | Biofidelity
Dec 10. 2020
Biofidelity Ltd, the cancer diagnostics company, today announces the further expansion of its leadership team with the appointment of Dr. Robert Osborne as …
Biofidelity opens new headquarters as part of significant expansion and drive to commercialization | Biofidelity
Dec 1. 2020
Expansion into new HQ comes as part of significant growth and drive to commercialization of Biofidelity’s first products Biofidelity Ltd, the cancer …
Biofidelity appoints Stephen Miller as Chief Commercial Officer | Biofidelity
Sep 17. 2020
Experienced US-based commercial leader joins Biofidelity prior to launch of disruptive cancer diagnostic platform US diagnostics executive with more than 25 …
Biofidelity appoints Dr. Heiner Dreismann as Chairman | Biofidelity
Sep 10. 2020
Board strengthened ahead of completion and market launch of disruptive cancer diagnostic platform Veteran Roche executive with more than 35 years of industry …
Biofidelity raises $12m in Series A financing to accelerate launch of disruptive cancer diagnostic technology | Biofidelity
Aug 20. 2020
Supported by BlueYard Capital, Longwall Ventures and Agilent Technologies Funds to be used to bring technology to market, enabling a dramatic simplification …
Biofidelity and Agilent complete successful molecular assay study for rapid and accurate detection of key lung cancer mutations | Biofidelity
Jan 9. 2020
Biofidelity Ltd, a company developing high performing novel molecular assays for the detection of targeted, low-frequency genetic mutations, today announced …
Biofidelity Awarded Innovate UK Grant to Develop Non-Invasive Tests to Enable Precision Medicine | Biofidelity
Oct 10. 2019
Biofidelity Ltd, a company providing advanced molecular assays for the sensitive detection of low-frequency genetic mutations, today announces it has …
Next-Gen Molecular Assay Play, Biofidelity Secures Seed Financing and Appoints Dr Heiner Dreismann as Senior Advisor | Biofidelity
Sep 3. 2019
Cambridge, UK, 3 September 2019 – Biofidelity Ltd, a company providing high performing novel molecular assays for the sensitive detection of low-frequency …